Chemerin biomarker is newly identified adipokine with a contentious part in people with metabolic syndrome. Chemerin is important in the development of progressive atherosclerosis. It is still very unclear how circulating chemerin and non-invasive indicators of subclinical atherosclerosis interact. To assess serum chemerin levels and atherosclerosis parameters in patients with metabolic syndrome. Methodology: 75 patients in metabolic syndrome who were undergoing the comprehensive health examinations were the subject of the cross-sectional investigation. Enzyme linked immunosorbent assay (ELISA) used to detect the serum chemerin level. High resolution ultrasonography was used to measure the carotid intima medial thickness, flow mediated vasodilatation and ankle brachial index in all subjects. Results: Those with metabolic syndrome, who had subclinical atherosclerosis, as shown by increased carotid intima medial thickness, flow mediated vasodilatation and ankle brachial index, had significantly higher serum chemerin levels. Positive associations in serum chemerin levels and patients with the metabolic syndrome based on a straight forward linear regression analysis. The level of chemerin in the serum significantly correlated positively with CIMT right (r=0.305), CIMT left (r=0.244) and a significant inverse correlation between serum chemerin with FMD (flow mediated vasodilatation) (r=-0.316), ABI (ankle brachial index) (r =-0.312); all "P" value of < 0.05 or lower is mentioned as significant. Conclusion: The subclinical atherosclerotic parameters that are being studied are a good indicator of the atherosclerotic burden in different artery sites and disease stage. The blood chemerin level was found to be a reliable predictor of atherosclerosis in people with metabolic syndrome